04:32 AM EDT, 06/03/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday a phase 3 trial showed its Imfinzi drug reducing the risk of death by 27% versus placebo in patients with limited-stage small-cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy.

The company said the drug, also known as durvalumab, is "the first and only immunotherapy" to show survival benefits for patients with limited-stage small-cell lung cancer.

The estimated median overall survival was 55.9 months for Imfinzi compared with 33.4 months for placebo, while an estimated 57% of patients treated with Imfinzi were alive at three years, compared with 48% on placebo, the company said.

Price: 77.84, Change: -0.18, Percent Change: -0.23